Momenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration...
Wednesday, December 28, 2011, 3:04 PM ETMomenta Pharmaceuticals (MNTA -1.8%) lands on the radar of analysts due to a lush collaboration deal it scored with Baxter and its strategic position in the growing "biosimilars" field. One estimate has the market for biotech generics running as high as $5B over the next few years, with drug offerings from firms such as MNTA and BIIB looking as a cheaper alternatives for strapped health care programs.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles